November 14-18, 2010, Morial Convention Center, New Orleans, USA

Visit the XSpray booth at this event and find out how RightSize™ Particle technology could benefit your work. We look forward to seeing you in New Orleans.

 ———————————————————————————–

More information about this event:

http://www.pswc2010.org/

In 2010 FIP and AAPS have agreed to hold the PSWC and the AAPS Annual Meeting together in New Orleans, Louisiana, USA from 14–18 November. FIP and AAPS also agree that the objective of this joint meeting should be for the education and benefit of the members of each organization and the constituencies that they represent. The programming, exposition, and other events will provide maximum educational opportunities.

The joint meeting will include:

-  A forum for the exchange of ideas and information about the sciences that the organizations represent
-  Continuing professional development for individual members and related professionals
-  An introduction of the latest technological advances

The scientific theme is: Improving Global Health Through Advances in Pharmaceutical Sciences. The Scientific Programming Committee is geographically balanced with members from the Americas, Asia, and Europe.

Stockholm, Sweden – August 20, 2009. XSpray Microparticles AB, the Swedish life science technology company, today announced the launch of its new GMP production facility in Malmö, Sweden. This means, in addition to offering particle development and characterization services, XSpray can now provide its customers with high quality drug particles and powders for use in their clinical studies.

XSpray’s RightSize™ Particle Manufacturing Technology is a ground-breaking solution for pharmaceutical particle development and production based on supercritical fluid technology. It overcomes many of the drawbacks of traditional micronization and is well suited to demanding applications, such as inhaled compounds, sparingly soluble compounds and biopharmaceuticals. As well as offering all the advantages of earlier supercritical fluid technologies it also enables full scalability.

The new GMP facility has been developed in collaboration with Galenica AB, an established Swedish CRO focused on pharmaceutical formulation. Manufacturing will be carried out by Galenica at the company’s state-of-the-art GMP suites in Malmö, Sweden.

XSpray’s CEO, Per Andersson, said, “We are extremely pleased to have this facility in place. Not only does it mean that we can now satisfy our customers’ needs for GMP material but it is also proof of the scale-up capability of the technology. As such, it is an important step towards developing full pharmaceutical manufacturing capabilities.” Dr. Andersson continued, “We are also very pleased with the collaboration with Galenica. We have every confidence that our customers will benefit from an extremely high quality, professional service.”

Galenica’s CEO, Ronnie Wallin, added, “Testing of the technology has gone very smoothly and we have established a production capacity that meets clinical study requirements. Our facilities comply with both EU and US regulatory standards and, in addition to manufacturing, we also provide packaging and release testing services. We are currently in the final stage of installation and are able to start manufacturing for XSpray’s customers as soon as required.”

For more information, please contact:
Per Andersson, CEO, XSpray Microparticles AB
Tel: +46 (0)8 730 37 00 
Email: per.andersson@xspray.com 

About XSpray
XSpray Microparticles AB is a Swedish life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. The Company’s cutting-edge platform technology – RightSize™ Particle Manufacture – uses supercritical fluid as an antisolvent for controlled precipitation of an active pharmaceutical ingredient/drug substance. The technology not only provides a superior process to traditional methods but also delivers better quality pharmaceutical particles, from discovery to production.

The process yields consistent powder particles in terms of size, shape and morphology that simplify formulation and can be incorporated into a variety of dosage forms, such as tablets, capsules and inhalation systems. RightSize Particle Manufacture addresses unmet therapeutic needs by enabling the development of drugs with enhanced delivery options, such as faster onset of action, and by adding innovative properties that truly benefit patients.

A key advantage of RightSize Particle Manufacture is that it can be effectively scaled up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles.

XSpray Microparticles has its headquarters and development laboratories in Stockholm, Sweden, and offers GMP production at a state-of-the-art GMP manufacturing facility in Malmö, Sweden. Find out more at: www.xspray.com

About Galenica
Galenica is a pharmaceutical technology CRO located in Malmö, Sweden. The company  offers preformulation and formulation, analysis, stability studies, documentation (CMC), GMP production together with project management. Galenica is authorized and audited by the Swedish Medical Agency for GMP production of clinical trial material for Phase I-III. The company has broad skills and experience in development projects and manufacturing of pharmaceutical preparations, comprising the most common types of dosage forms. Galenica can assist within all phases of a project, from the identification of an efficacious substance until a complete pharmaceutical is in commercial production. For more information see:  www.galenica.se

Stockholm, Sweden – April 20, 2009. Xspray Microparticles AB, the Swedish life science technology company, has developed a cutting-edge solution for pharmaceutical particle production based on supercritical fluid technology. The Company’s RightSize Particle Manufacturing Technology overcomes many of the drawbacks of traditional micronization and is well suited to demanding applications. As well as offering all the advantages of earlier supercritical fluid technologies it also provides scalability. This means pharmaceutical companies have the opportunity to produce better quality particles and powders, from discovery all the way through to drug manufacture.

The first commercial agreement with a customer began in Q4, 2008. Since then, two additional, major pharmaceutical companies have also undertaken evaluation projects. Each of the companies is using the technology for a different purpose; one is studying crystallization, another is looking at solid dispersion and the third is working with nanonization (the production of nano-sized particles).

”Interest from pharmaceutical companies has been steadily increasing over the last twelve months or so,” commented Per Andersson, Xspray’s CEO. ”Despite the current economical climate we have secured three commercial agreements, which shows that customers are convinced by the benefits of the technology. This is an important step for the Company and confirms that we have a strong offering, capable of adding real value throughout the pharmaceutical process from development to production.”

To support the ongoing evaluation projects, and to meet an expected increase in future demand, Xspray has recently doubled the size of its service lab. The strengthening of human resources began in mid 2008 with the appointment of Mikael Bisrat as Chief Scientific Officer. Dr. Bisrat has more than 15 years experience in the industry and has a thorough understanding of the needs within pharmaceutical development projects. The most recent recruit is Helene Dérand, PhD, who joined the company in March 2009 as Sales and Marketing Director. Ms Dérand has broad-based experience gained from more than ten years in the biotechnology and medical technology sectors. She has held various management positions in both global and start-up companies with responsibilities ranging from R&D and clinical operations to business development.

Per Andersson continued, “We have recently expanded our service offering to include solid state characterization and analysis capabilities. Plus, we will be opening our new GMP production facility within the next month or so. There are some exciting opportunities ahead for Xspray, so it is important that we have a capable, dynamic organization in place to take full advantage of them.”

For more information, please contact:
Per Andersson, CEO, Xspray Microparticles AB
Tel: +46 (0)8 730 37 00   Email: per.andersson@xspray.com  

About Xspray
Xspray Microparticles AB is a Swedish life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. The Company’s cutting-edge platform technology – RightSize™ Particle Manufacture – uses supercritical fluid as an antisolvent for controlled precipitation of an active pharmaceutical ingredient/drug substance. The technology not only provides a superior process to traditional methods but also delivers better quality pharmaceutical particles, from discovery to production.

The process yields consistent powder particles in terms of size, shape and morphology that simplify formulation and can be incorporated into a variety of dosage forms, such as tablets, capsules, and inhalation systems. RightSize Particle Manufacture addresses unmet therapeutic needs by enabling the development of drugs with enhanced delivery options, such as faster onset of action, and by adding innovative properties that truly benefit patients.

A key advantage of RightSize Particle Manufacture is that it can be effectively scaled up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles.

Xspray Microparticles has its headquarters and development laboratories in Stockholm, Sweden.

Stockholm, Sweden – December 01, 2008. The Swedish life science technology company, Xspray Microparticles AB, now offers solid state characterization services to complement its cutting-edge solution for pharmaceutical particle production. The new service will allow the Company to reduce project development times by offering high quality characterization and analysis of solid state particle properties. 

Dr. Mikael Bisrat, who joined Xspray in mid 2008 as Chief Scientific Officer, is responsible for the new service area. Dr. Bisrat has more than 15 years experience in the pharmaceutical industry, including several positions overseeing solid state characterization. In addition to his analytical skills, Dr. Bisrat also has a thorough understanding of the underlying needs within pharmaceutical development projects.

“At Xspray we are offering a high quality analysis service that is capable of meeting specific project and customer requirements. Using the latest analytical procedures and techniques we are able to provide comprehensive characterization of pharmaceutical solids,” commented Dr. Bisrat.

Xspray’s CEO, Per Andersson, explains the value of the new service, “We are obviously delighted to have someone of Mikael’s background and experience behind this initiative. It means we now have some fantastic resources in this area, which should greatly benefit our customers. Not only will it improve the infrastructure within development work but it will speed up the whole process. Rather than waiting on external lab resources we can now generate our own data far more quickly.”

The new service is available for both Xspray manufactured powders and particles, and those produced by third parties.

About Xspray
Xspray Microparticles AB is a Swedish life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. The Company’s cutting-edge platform technology – RightSize™ Particle Manufacture – uses supercritical fluid as an antisolvent for controlled precipitation of an active pharmaceutical ingredient/drug substance. The technology not only provides a superior process to traditional methods but also delivers better quality pharmaceutical particles, from discovery to production.

The process yields consistent powder particles in terms of size, shape and morphology that simplify formulation and can be incorporated into a variety of dosage forms, such as tablets, capsules, and inhalation systems. RightSize Particle Manufacture addresses unmet therapeutic needs by enabling the development of drugs with enhanced delivery options, such as faster onset of action, and by adding innovative properties that truly benefit patients.

A key advantage of RightSize Particle Manufacture is that it can be effectively scaled up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles.

Xspray Microparticles has its headquarters and development laboratories in Stockholm, Sweden.

Stockholm, Sweden – August 01, 2008. Xspray Microparticles AB, the Swedish life science technology company, has appointed Dr. Mikael Bisrat, PhD, as Chief Scientific Officer. The appointment comes at a time when several pharmaceutical companies begin evaluations of Xspray’s cutting-edge particle production technology.

Prior to joining Xspray Dr. Bisrat was Director of Pharmaceutics at Biovitrum. He has more than 15 years of industrial experience as a formulation scientist, a research scientist and in managerial positions. His roles have included Associate Director Pharmaceutical Development at AstraZeneca and Director Pharmaceutics at Pharmacia Upjohn.

Commenting on the appointment, Per Andersson, Xspray’s CEO, said, “We are obviously extremely pleased to have someone with Mikael’s extensive experience on board. It is a crucial time for the Company as we start working directly with customer projects. Mikeal’s capabilities are an important factor both in terms of ensuring successful customer development projects and for Xspray’s long term strategic growth.” 

Dr. Bisrat is a co-author of three patents in the area of supercritical crystallization and he is also one of the co-founders of Xspray Microparticles. As such, he has a thorough understanding of the technology. “I am very excited about joining Xspray in a managerial capacity. RightSize Particle Manufacture has fantastic potential. It is a robust technology, but most importantly it allows companies to produce high quality particles right through the pharmaceutical development process, from discovery to manufacture,” commented Dr. Bisrat.

About Xspray
Xspray Microparticles AB is a Swedish life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. The Company’s cutting-edge platform technology – RightSize™ Particle Manufacture – uses supercritical fluid as an antisolvent for controlled precipitation of an active pharmaceutical ingredient/drug substance. The technology not only provides a superior process to traditional methods but also delivers better quality pharmaceutical particles, from discovery to production.

The process yields consistent powder particles in terms of size, shape and morphology that simplify formulation and can be incorporated into a variety of dosage forms, such as tablets, capsules, and inhalation systems. RightSize Particle Manufacture addresses unmet therapeutic needs by enabling the development of drugs with enhanced delivery options, such as faster onset of action, and by adding innovative properties that truly benefit patients.

A key advantage of RightSize Particle Manufacture is that it can be effectively scaled up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles.

Xspray Microparticles has its headquarters and development laboratories in Stockholm, Sweden.

Stockholm, Sweden- November 9, 2007 – Xspray™ Microparticles AB a private company leading the development of super critical fluid technology for the manufacture of pharmaceutical particles announces financing has been approved to take it’s RightSize™ Particle Manufacture technology to GMP.

The new financing is a milestone payment, based on successful scale up of the RightSize Particle manufacture technology. It will be used to set up a fully validated GMP facility and will allow the company to implement the next stage in its strategy; manufacture of pharmaceutical particles under GMP condition with RightSize Particle Manufacture technology. Positioning Xspray Microparticles at the forefront of pharmaceutical manufacturing using supercritical fluid technology. The company will be presenting this technology at a seminar during the annual AAPS meeting in San Diego on the 14^th November, where Prof. Peter York, an acknowledged expert on pharmaceutical particle engineering will also be speaking.

RightSize Particle Manufacture technology is clearly differentiated by its scalability which makes this an ideal technology for the drug development process, being able to work at the scales needed from discovery through to production. ‘’Supercritical fluid technology has been developing over the last 20 years and has clearly demonstrated many advantages for producing pharmaceutical powders’’ Stated Dr. Per Andersson CEO of Xspray Microparticles, “but in the past scaling to the extent needed for pharmaceutical production has been challenging. The ease with which RightSize particle manufacture can be scaled opens the doors for pharmaceutical companies to reap the rewards offered by supercritical fluid technology.

About Xspray Microparticles AB

Xspray Microparticles is a development company with in depth knowledge of both super critical fluid technology and the drug development process; developing cutting edge platform technologies and offering solutions for the production of customised pharmaceutical particulate material. The process yields consistent powder particles in terms of size, shape and morphology that can be incorporated into a number of dosage forms including tablets, capsules, and inhalation systems addressing areas of unmet therapeutic need by enabling the development of drugs with enhanced delivery options, faster onset of action and adding innovative properties that really benefit patients. The unique ability to scale up the SCF RightSize Particle Manufacture technology enables super critical fluid technology to be used for the production of pharmaceutical particulates, enabling particle engineering for the production of pharmaceutical particulates.
More information about the company can be found at www.xspray.com

Xspray Microparticles has its global headquarters and development laboratories in Stockholm, Sweden

Stockholm, Sweden- October 15, 2007 – Xspray Microparticles AB, a private company developing technologies for Manufacture of pharmaceutical particles using super critical fluid technology announces the appointment of Gérald Jesson, to the position of V.P Operations.

“This appointment is part of ongoing efforts to enhance our management team as we sharpen our focus on the introduction of the SCF RightSize™ Particle Manufacture Technology. We have now proven the scale up capabilities of this technology which enables the rebirth of super critical fluid technology for the production of pharmaceutical particles’ said Dr. Per Andersson CEO of Xspray Microparticles. “I’d like to welcome Gérald and his 11 years of experience in developing high tech technologies for the biotechnology market this will be an important factor in Xspray’s strategic growth and success.”

Gérald Jesson joined Xspray Microparticles in September 2007. His accomplishments include founding two companies in Sweden, one of which, Capture Device AB was sold to Biomotif AB in 2007 He worked for Gyros AB for 7 years, and has rights to 15 patents. He has also worked at the Karolinska Institute in Stockholm and VIRBAC S.A. based in Nice, France. ‘I am really excited about joining XSpray’ said Mr.Jesson ‘The SCF RightSize Technology is impressively simple and robust; being able to produce high quality particles right through the pharmaceutical development process from discovery to manufacture, This technology is the result of over ten years research and development led by Mustafa Demirbüker, who is now the CSO of Xspray Microparticles.’

About Xspray Microparticles AB

Xspray Microparticles is a development company with in depth knowledge of both super critical fluid technology and the drug development process; developing cutting edge platform technologies and offering solutions for the production of customised pharmaceutical particulate material. The process yields consistent powder particles in terms of size, shape and morphology that can be incorporated into a number of dosage forms including tablets, capsules, and inhalation systems addressing areas of unmet therapeutic need by enabling the development of drugs with enhanced delivery options, faster onset of action and adding innovative properties that really benefit patients.
The unique ability to scale up the SCF RightSize Particle Manufacture technology enables super critical fluid technology to be used for the production of pharmaceutical particulates, enabling particle engineering for the production of pharmaceutical particulates.
More information about the company can be found at www.xspray.com